Improving Results for Express Scripts
The Cigna merger is on track, and we are maintaining our $92 fair value estimate and wide moat rating after a solid quarter for Express Scripts.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.